Sanofi Accelerates Its Timeline For Coronavirus Vaccine Development
via https://youtu.be/obTWR2RXsEI After lagging behind its competitors in starting clinical trials, the French drugmaker Sanofi has announced plans to speed a vaccine development timeline that could yield approval from regulatory authorities sometime next year, perhaps in the first half of 2021, the company announced on Tuesday. The company and its partner in the endeavor, GlaxoSmithKline, originally projected that a vaccine would be available, at the earliest, in the latter half of next year. Like other contenders in the race for a coronavirus vaccine, Sanofi is eager to push forward. such fast-tracking and intense scale of vaccine production is totally unprecedented — Padmini Pillai The Sanofi-GSK vaccine contains a laboratory-synthesized version of the coronavirus’s “spike” protein, which decorates the surface of the virus and is crucial to its ability to enter host cells. In news briefings on Tuesday, both companies expressed confidence in their collaboration and its potential to deliver a successful vaccine. Sanofi’s history with vaccine development runs deep; its production lines are responsible for hundreds of millions of doses of the flu vaccine each year. Sanofi is also developing a separate set of vaccine candidates with Translate Bio, an American therapeutics company, on a slightly less expedited timeline. Such mRNA vaccines are new; to date, none have been cleared for use in humans. Pakistan Ka Showbiz
No comments:
Post a Comment